| Date | Title | | | December 20, 2011 | Incyte to Present at the 30th Annual J. P. Morgan Healthcare Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 20, 2011--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
30th Annual J. P. Morgan Healthcare Conference on Monday,
January 9, 2012 at 8:30 a.m. (PT) / 11:30 a.m. (ET) in San Francisco.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors in... |
|  | | December 12, 2011 | First FDA-Approved Treatment for Myelofibrosis, Jakafi™ (ruxolitinib), Discussed in Multiple Presentations at 2011 ASH Annual Meeting|
Incyte to host a webcast for investors featuring these results on
Monday, December 12 at 7:00 p.m. PT
SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2011--
Incyte Corporation (Nasdaq:INCY) today announced that further analyses
from the global, pivotal Phase III clinical program of Jakafi
(ruxolitinib or INC424) are being presented at the 2011 American Society
of Hematology (ASH) Annual Meeting. The presentations include:
Verstovsek S, et... |
| | | November 30, 2011 | Incyte to Present at the Oppenheimer & Co. 22nd
AnnualHealthcare Conference| WILMINGTON, Del., Nov 30, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Oppenheimer & Co. 22nd Annual Healthcare Conference on
Wednesday, December 14, 2011 at 3:20 p.m. (ET) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
listenin... |
| | | November 18, 2011 | Incyte to Present at the 23rd Annual Piper Jaffray Health Care Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 18, 2011--
Incyte Corporation (Nasdaq:INCY) announced today it will present at the
23rd Annual Piper Jaffray Health Care Conference on Tuesday,
November 29, 2011 at 4:30 p.m. (ET) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 30 days. Investors interested in
... |
| | | November 16, 2011 | FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis|
- First and Only FDA-Approved Treatment For Potentially
Life-Threatening Blood Cancer
- Product Available Next Week; Incyte Establishes Comprehensive
Patient Assistance Program
- Conference Call Scheduled, Today at 12:30 PM ET
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 16, 2011--
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and
Drug Administration (FDA) has granted marketing approval for Jakafi™
... |
| | | October 27, 2011 | Incyte Reports Third Quarter 2011 Financial Results and Provides Update
on Key Clinical Programs|
New Drug Application (NDA) for ruxolitinib as a treatment for
myelofibrosis filed and granted priority review by the US Food and
Drug Administration (FDA); PDUFA date set for December 3, 2011
Commercialization activities advance; sales force recruitment completed
Amendment to the Special Protocol Assessment (SPA) for RESPONSE, the
Phase III trial for patients with advanced polycythemia vera, a... |
| | | October 13, 2011 | Incyte to Report Third Quarter 2011 Financial Results and Provide Update on Key Clinical Programs on October 27| WILMINGTON, Del., Oct 13, 2011 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2011 financial results conference call for 8:30 a.m. ET on Thursday, October 27, 2011. The schedules for the press release and conference call are as follows:
-- Q3 2011 Press Release:
October 27, 2011 at 7:00 a.m. ET
-- Q3 2011 Conference Call:
October 27, 2011 at 8:30 a.m. ET
-- Domestic Dial In Number:
877-407-8037
-- Inter... |
| | | August 30, 2011 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del., Aug 30, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of September:
Robert W. Baird & Co. 2011 Health Care Conference on Thursday,
September 8, 2011 at 1:45 p.m. (ET) in New York City;
Morgan Stanley Global Healthcare Conference on Wednesday, September
14, 2011 at 11:30 a.m. (ET) in New York City;
... |
| | | August 03, 2011 | FDA Accepts NDA Filing for Ruxolitinib as a Treatment for
Myelofibrosis|
Application Granted Priority Review
PDUFA Date Set for December 3, 2011
WILMINGTON, Del., Aug 03, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today that the US Food and
Drug Administration (FDA) has accepted for filing the New Drug
Application (NDA) for Incyte's lead investigational compound,
ruxolitinib (INCB18424/INC424), as a potential treatment for patients
with myelofibrosis (MF). MF is a potentially life-thre... |
| | | July 28, 2011 | Incyte Reports Second Quarter 2011 Financial Results and Provides Update
on Key Clinical Programs|
New Drug Application (NDA) for ruxolitinib as a treatment for
myelofibrosis submitted to US Food & Drug Administration (FDA)
Pivotal Phase III results for ruxolitinib demonstrating significant
clinical benefit in patients with myelofibrosis presented at ASCO and
EHA
Commercialization activities ongoing; sales force recruitment initiated
Conference Call Scheduled Today at 8:3... |
| | | July 13, 2011 | Incyte Reports Second Quarter 2011 Financial Results andProvides
Update on Key Clinical Programs on July 28| WILMINGTON, Del., Jul 13, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its second quarter 2011 financial results conference call for 8:30 a.m.
ET on Thursday, July 28, 2011. The schedules for the press release and
conference call are as follows:
-- Q2 2011 Press Release:
July 28, 2011 at 7:00 a.m. ET
... |
| | | June 11, 2011 | Incyte Reports Additional Analyses of Symptomatic Improvement andQuality
of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from
the COMFORT-I Study| Results Presented at 16th Congress of the European Hematology
Association
LONDON, Jun 11, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today additional symptom
improvement and quality of life (QoL) results from COMFORT-I (COntrolled
MyeloFibrosis
Study with ORal JAK inhibitor Treatment),
a randomized, double-blinded, placebo-controlled Phase III trial of
Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with
... |
| | | June 06, 2011 | Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration| WILMINGTON, Del., Jun 06, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today that it has submitted a
New Drug Application (NDA) for its lead investigational compound,
ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).
Incyte is seeking US marketing approval of ruxolitinib for the treatment
of myelofibrosis (MF), a potentially life-threatening blood cancer for
which there are currently no approved therapies in the US... |
| | | June 04, 2011 | Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical
Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO
Annual Meeting|
A potentially life-threatening blood cancer with limited treatment
options, myelofibrosis is characterized by bone marrow failure,
enlarged spleen and highly debilitating symptoms
Both Phase III studies, COMFORT-I conducted by Incyte and
COMFORT-II conducted by Novartis, met their primary efficacy endpoint
and provide the basis for US and EU filings in June
Highlights from the ruxolitinib clinical program are being reported
... |
| | | May 24, 2011 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del., May 24, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the
following investor conferences during the month of June:
Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011
at 11:30 a.m. (ET) in New York City;
Goldman Sachs 32nd Annual Global Healthcare Conference on
Wednesday, June 8, 2011 at 2:40 p.m. (PT) in California; and
... |
| | | May 03, 2011 | Incyte Reports First Quarter 2011 Financial Results and Program
Updates|
Second Phase III Trial of Ruxolitinib, COMFORT-II, Conducted by
Novartis, Achieved Primary Endpoint in First Quarter
Ruxolitinib U.S. and E.U. Regulatory Submissions on Track for Second
Quarter
Data from COMFORT-I and COMFORT-II Accepted for Oral Presentations at
ASCO and EHA
Conference Call Scheduled Today at 8:30 a.m. ET
WILMINGTON, Del., May 03, 2011 (BUSINESS WIRE) --Incy... |
| | | April 27, 2011 | Incyte to Present at the Bank of America Merrill Lynch Healthcare
Conference| WILMINGTON, Del., Apr 27, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10,
2011 at 4:20 p.m. (PT) / 7:20 p.m. (ET) in Las Vegas, NV.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 30 days. Investors interested in
... |
| | | April 14, 2011 | Incyte to Report First Quarter 2011 Financial Results and Provide
Update on Drug Discovery & Development Programs on May 3| WILMINGTON, Del., Apr 14, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its first quarter 2011 financial results conference call for 8:30 a.m.
ET on Tuesday, May 3, 2011. The schedules for the press release and
conference call are as follows:
-- Q1 2011 Press Release:
May 3, 2011 at 7:00 a.m. ET
... |
| | | April 05, 2011 | Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology
Program| WILMINGTON, Del., Apr 05, 2011 (BUSINESS WIRE) --Incyte Corporation (NASDAQ: INCY) announced today that it has earned a
$15 million payment from Novartis based on the achievement of a
predefined milestone in an ongoing Phase I dose- escalation trial for
INCB28060 (also known as INC280) in patients with solid tumors. This
trial is being conducted by Incyte as part of its worldwide
collaboration and license agreement with Novartis under which Incyte
... |
| | | March 15, 2011 | Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint in Second
Phase III Study|
Data from Novartis COMFORT-II European Phase III trial show
treatment with ruxolitinib provided a statistically significant
reduction in spleen size in patients with myelofibrosis when compared
with best available therapy
Myelofibrosis is a debilitating disease with a poor prognosis and
limited therapies, presenting a critical unmet medical need
US New Drug Application submission by Incyte and EU Marketing
Authorizatio... |
| | | February 23, 2011 | Incyte to Present at the Cowen and Company 31st
Annual Health Care Conference| WILMINGTON, Del., Feb 23, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Cowen and Company 31st Annual Health Care Conference on
Wednesday, March 9, 2011 at 9:30 a.m. (ET) in Boston.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 30 days. Investors interested in
listening to the ... |
| | | February 10, 2011 | Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives
and Financial Guidance| --Positive clinical results and strong financial position advance
Company towards commercialization --
Conference Call Scheduled Today at 8:30 a.m. ET
WILMINGTON, Del., Feb 10, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) today reported fourth quarter and full
year 2010 financial results, provided 2011 key objectives, and announced
its 2011 financial guidance.
"The advancements made in all of our clinical programs in 2010 were
remarkable, espec... |
| | | January 28, 2011 | Incyte to Report 2010 Financial Results and Provide 2011 Key Objectives and Financial Guidance on February 10| WILMINGTON, Del., Jan 28, 2011 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter/year-end 2010 financial results conference call for 8:30 a.m. ET on Thursday, February 10, 2011. The schedules for the press release and conference call are as follows:
Q4 & YE 2010 Press Release:
February 10, 2011 at 7:00 a.m. ET
Q4 & YE 2010 Conference Call:
February 10, 2011 at 8:30 a.m. ET
Domestic Dial In Number:
877-407-8037
... |
| | | January 03, 2011 | Incyte to Present at the 29th Annual J.P. Morgan Healthcare Conference| WILMINGTON, Del., Jan 03, 2011 (BUSINESS WIRE) --Incyte Corporation (Nasdaq:INCY) announced today it will present at the
29th Annual J.P. Morgan Healthcare Conference on Tuesday,
January 11, 2011 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 30 days. Investors interested in
li... |
| |
|
